GE Healthcare

GE HealthCare (Nasdaq: GEHC) + announced today that it launched its CardioVisio digital tool for helping to treat AFib.

CardioVisio assists clinicians in visualizing longitudinal data relevant for disease progression from multiple data sources. It drives evidence-based clinical decision support directed by up-to-date AFib guidelines.

GE HealthCare plans to showcase the technology at the European Society of Cardiology (ESC) Congress in Amsterdam this week.

By helping clinicians visualize data, CardioVisio can save time and aid decision-making with guideline-directed therapy recommendations. Each automated step includes explainability and traceability. GE HealthCare said this enables the provider to audit and edit the process and output.

Ultimately, the company says, it aims to better meet the needs of each unique AFib patient.

“Existing diagnosis and treatment care models for AFib have been shown to…

The Portrait Mobile system. [Image courtesy of GE HealthCare]GE HealthCare (Nasdaq: GEHC) + announced today that it received FDA 510(k) clearance for its Portrait Mobile wireless and wearable monitoring solution.

Portrait Mobile enables real-time continuous monitoring with a personalized view of a patient’s vitals. It also keeps patients mobile during critical recovery periods, including after surgery or ICU discharge.

According to GE HealthCare, continuous monitoring and real-time data viewing can help clinicians recognize deterioration earlier than traditional spot-check methods. Those checks only occur about every 4-6 hours. Wireless, patient-worn sensors, combined with the smartphone-sized monitor, eliminate all traditional tethers. GE HealthCare says this enables patients to move freely around the ward, helping to improve outcomes and reduce the length of stay.

Portrait Mobile aims to modernize respirati…

The FDA issued a notice labeling the GE HealthCare (Nasdaq: GEHC) + SpO2 sensor recall as Class I, the most serious kind.

GE HealthCare initiated the recall of nine models of its TruSignal SpO2 sensor on May 19, 2023. The recall includes 7,559 devices distributed between Jan. 1, 2021, and March 4, 2023.

TruSignal sensors continuously monitor the amount of oxygen found in the blood flowing through the arteries and pulse rate. Placed on the skin, the sensors help to ensure that patients have enough oxygen in their blood to continue functioning. They also help care providers garner information necessary to make treatment decisions.

Why GE HealthCare recalled the sensors

GE HealthCare recalled malfunctioning TruSignal sensors that may reduce the amount of energy sent to the heart during defibrillation. This issue occurs without any notification to the care provider. Without notification, this could prevent the deliv…

GE HealthCare (Nasdaq: GEHC) + shares were down today, even though second-quarter results topped the consensus forecast.

Shares of GEHC initially rose, but were down slightly to $80.36 apiece by afternoon trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up slightly.

BTIG analysts said that with orders facing more challenging comps for the rest of the year at the same time that management raises guidance, investors might view GE HealthCare’s situation as more challenging.

The Chicago-based company posted profits of $418 million. That amounts to 91¢ per share on sales of $4.817 billion for the three months ended June 30, 2023.

GE HealthCare recorded a 13.8% bottom-line slide on sales growth of 7.4%.

Adjusted to exclude one-time items, earnings per share totaled 92¢. That landed 5¢ ahead of projections on Wall…

The Signa PET/MR AIR system. [Image courtesy of GE HealthCare]GE HealthCare (Nasdaq: GEHC) + announced its plans to unveil its Signa PET/MR AIR technologies for enhancing imaging.

The company intends to unveil the new technology at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 annual meeting. It said the platform showcases the integration of advanced AIR technologies with SIGNA, enhancing diagnostic precision. Signa also can simplify treatment evaluation and elevate patient comfort, GE HealthCare said in a news release.

GE HealthCare says the AIR technologies incorporated into Signa address the evolving demands of a range of patient populations. New PET radiotracers and therapeutic approaches treat high-prevalence diseases such as prostate cancer and Alzheimer’s disease.

The system features AIR Coils, which enhance and improve patient comfort, GE HealthCare says. It also includes AIR Reco…

GE HealthCare (Nasdaq:GEHC) announced today that it launched its now FDA-cleared Sonic DL MRI technology.

Chicago-based GE HealthCare developed Sonic DL as a state-of-the-art deep learning-based technology. The company designed it to accelerate image acquisition in magnetic resonance imaging (MRI).

This platform could enable new imaging paradigms, including high-quality cardiac MRI in a single heartbeat, the company says. It marks the latest addition to the growth AI-enabled product portfolio at GE HealthCare.

GE HealthCare said in a news release that lengthy exam times limit the global adoption of cardiac MRI. Current methods take too long to capture the heart’s contraction in real-time, the company explained. This requires several heartbeats and multiple breath-holds to acquire images.

The time-consuming process also faces limitations in image quality, with degradation playing a role. GE HealthCare said Sonic DL scans up to 12 times faster…

GE HealthCare shares took a hit today despite first-quarter results that topped the consensus forecast.

Shares of GEHC were down more than 9% to $79.83 apiece by afternoon trading today. Some suggest disappointment that the company didn’t raise its guidance as the reason behind that dip. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — fell more than 1%.

GE HealthCare reaffirmed its guidance for 2023 with its sales growth range of 5% to 7% mentioned by Arduini. The company projects adjusted EPS to range between $3.60 to $3.75. BTIG analyst Ryan Zimmerman noted that investors expected a guidance raise. That may impact the reaction on the market.

Additionally, Zimmerman pointed out that investors may look negatively upon a decrease in orders. Combined with the guidance and a “normalized growth cadence,” GE HealthCare could face a “tougher set-up” through the y…